CSL EBIT 2017-2024 | CSLLY

CSL EBIT for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL 2024 EBIT was 3.812B, a 24.21% increase from 2023.
  • CSL 2023 EBIT was 3.069B, a 4.85% increase from 2022.
  • CSL 2022 EBIT was 2.927B, a 6.49% decline from 2021.

EBIT can be defined as earnings before interest and taxes.

CSL EBIT 2017-2024 | CSLLY

  • CSL 2024 EBIT was 3.812B, a 24.21% increase from 2023.
  • CSL 2023 EBIT was 3.069B, a 4.85% increase from 2022.
  • CSL 2022 EBIT was 2.927B, a 6.49% decline from 2021.

EBIT can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$251.1B
Amgen (AMGN)$158.1B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$101.3B
Bristol Myers Squibb (BMY)$97.5B
GSK (GSK)$81.9B
Regeneron Pharmaceuticals (REGN)$62.5B
Alnylam Pharmaceuticals (ALNY)$59.6B
Argenex SE (ARGX)$40.4B
Insmed (INSM)$27.9B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$21.2B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.1B
Genmab (GMAB)$15.8B
Illumina (ILMN)$15.6B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Moderna (MRNA)$10.6B
Exelixis (EXEL)$10.4B
Verona Pharma American Depositary Share (VRNA)$9.1B
Exact Sciences (EXAS)$9B
Bio-Techne Corp (TECH)$8.9B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Guardant Health (GH)$7.7B